Results 11 to 20 of about 10,082 (205)
Therapeutic Advances in Endocrinology and Metabolism, 2018 Background: Fast-acting insulin aspart is a new formulation of the rapid-acting insulin analogue insulin aspart and represents an advancement over current rapid-acting insulin analogues in terms of onset of action and postprandial glucose control.
Lalantha Leelarathna +3 more
doaj +2 more sources
Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
Vascular Health and Risk Management, 2008 Nazia Raja-Khan, Sarah S Warehime, Robert A GabbayDivision of Endocrinology, Diabetes, and Metabolism, Penn State Institute for Diabetes and Obesity, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USABackground: Insulin is an ...
Nazia Raja-Khan +2 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sudhir Tripathi +3 more
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Alaa Daban, Hussain Haji Ali
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Uday Phadke +2 more
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Neeta Deshpande +4 more
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sreejith N Kumar, Tom Babu, V M Haridas
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Hicham Boussouf +2 more
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
El Ansari Nawal
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Moody El Harby, Ahmed Saeed
doaj +2 more sources